Why Attend
Our speakers will explore ground-breaking developments surrounding CRISPR and utilising all genome editing tools as a therapy. It will focus on advancements to overcome ‘off targets’, delivery approaches for in vivo applications and efficacy considerations across patient diversity.
- CRISPR Therapeutics’ TJ Cradick and Cellectis’ Stefan Scherer will share their clinical trial experiences within therapeutic genome editing applications
- Harvard’s Richard Sherwood will share how to improve CRISPR safety by utilizing machine learning
- Casebia’s Abraham Scaria will offer delivery guidance to progress in vivo applications
In an extremely busy and exciting space it can be hard to pick out the top tool innovations to increase precision and properly discuss clinical challenges, this meeting will facilitate this. It will provide an opportunity with engage with the leading experts who are working on new platforms, leading the clinical trials and have patient insights. It is also a forum to build collaborations to create a clinically and commercially viable, effective and safe approach within gene and cell therapy medicine.
‘CRISPR medicines have the potential to transform the treatment for rare genetic and perhaps common diseases; the challenge for scientists is to demonstrate that these medicines can be both safe and effective’ – Steve Rees, VP of Discovery Biology, AstraZeneca
SPEAKERS FROM
The Speakers
George Church
Steve Rees
Steve Rees is Vice-President of the Discovery Biology department at AstraZeneca with global responsibility for reagent generation, assay development and functional genomics. Prior to this Steve led the Screening Sciences and Sample Management department at AstraZeneca with accountability for Compound Management, the human tissue BioBank, Hit Discovery and Lead Optimisation biology support to preclinical discovery projects. Prior to joining AstraZeneca, Steve worked at GlaxoSmithKline for 24 years in various roles. Steve has led multiple international collaborations, has authored >65 scientific papers and has spoken at many international symposia. He is currently Chairman of the European laboratory Research and Innovation Group, and a member of the Scientific Advisory Board for LifeArc, the Centre for Membrane Protein Receptor Research at the Universities of Birmingham and Nottingham and Axol Bioscience Ltd.
TJ Cradick
Stefan Scherer
Dr. Alessandra Biffi
Issi Rozen
ISSI ROZEN, Chief Business Officer at the Broad Institute of Harvard and MIT, is responsible for partnering with the life sciences industry and venture investors and developing innovative scientific and business collaborations. He is also responsible for initiating and establishing new ventures around novel technologies and for licensing the institute’s intellectual property portfolio. He joined the Broad in 2011 after a career in the biotech industry. Before joining the Broad Institute, Rozen led corporate development at Resolvyx, a venture-backed biotech start-up. Before that, he headed the business analysis group at EMD Serono where he was responsible for evaluations of in-licensing and M&A opportunities as well as commercial analytics and forecasting for pipeline and commercial products. Issi is a co-founder of a number of biotech start-ups and is an accomplished jazz guitarist. He earned his M.B.A. at MIT’s Sloan School of Management.
Richard Sherwood
My lab combines high-throughput genomic screening with machine learning to understand genome function in normal and diseased contexts. My work aims to advance precise genomic medicine and novel gene therapy applications.
Samantha Maragh
Eric Kmiec
Niren Murthy
Abraham Scaria
Dr. Scaria obtained his Ph.D. in Molecular Biology from Indiana University School of Medicine in Indianapolis. He did postdoctoral training at St. Louis University School of Medicine working on RNA splicing mechanisms in adenoviruses and virus-host interactions. Dr. Scaria then worked as a Senior Fellow at University of Washington School of Medicine in Seattle before joining Genzyme Corporation to work on gene therapy for Cystic Fibrosis. At Genzyme and later at Sanofi-Genzyme, Dr. Scaria held various positions with increasing responsibilities for two decades finally heading up both the gene therapy research group and the ophthalmology research efforts. Currently, Dr. Scaria is the VP & Head of Ophthalmology at Casebia Therapeutics where he is developing gene-editing based therapies for ocular genetic diseases.
David Resnick
Dr Gurumurthy Channabasavaiah
Guru (CB Gurumurthy) received his BVSC (DVM) from Bangalore Veterinary College, India and MVSC & PHD in Veterinary Virology from Indian Veterinary Research Institute, with a Gold Medal distinction in MVSC, and an Executive MBA from University of Nebraska at Omaha. He is currently an Associate Professor of Developmental Neuroscience, Munroe Meyer Institute for Genetics and Rehabilitation at the University of Nebraska Medical Center. He is also the Director of the UNMC’s Mouse Genome Engineering Core Facility. His research interests are improving and development of novel genome engineering technologies. He is a co-developer of popular technologies such as Easi (Efficient additions with ssDNA-inserts)-CRISPR, CRISPR-first: PITT-next and GONAD (Genome Editing via Oviductal Nucleic Acids Delivery). Some of these technologies have already been adapted in many labs worldwide.
Dr Andrew Kernytsky
Professor Jeff Chamberlain
Dr Claudio Mussolino
Professor Harold Smith
Anna Krichevsky
Dr Eric Paul Bennett
Brian Burke
Brian joined Horizon in 2012 during which time he has led various functions including Sales, Business Development and Product Management. Much of his career has been focused in driving both the NGS and gene editing revolutions, most notably in the fields of diagnostics and bioprocessing. In 2018 he was promoted to the Global Head of Strategy and now leads Horizon’s Corporate Development efforts including strategy development and M&A.
Talk to Our Speakers About...
1. How to overcome off- targets through base editing and utilizing new Cas strains
2. New delivery systems to approach successful in vivo applications
3. How does patient diversity impact CRISPR efficacy?
4. Industry’s thoughts on the future of CRISPR/Cas tool in a therapeutic setting
5. How to apply genome editing and protocols for successful clinical trials
6. Key translational science skills essential for clinical development
7. The commercial viability of genome editing as a medicine, what are medical institutions looking for?
8. IP and licencing landscape surrounding genome editing tools to progress commercially
9. Rational analysis of risk benefit and disease identification
10. Ethical factors
Who Will Be There
-
Biotechs30%
-
Pharma20%
-
Academics15%
-
Clinicians & Physicians10%
-
Service Providers15%
-
Genome Editing Platform Technologies10&
The Agenda
Please download the agenda to find out more information about the congress including the main topics of discussion for the two days and our full lineup of speakers.
‘Outstanding comprehensive overview with top academic and industry experts’ - Juan Ruiz – JNJ
‘The diversity of technical approaches was very informative’ - David Wedlake - Celgene
‘Optimal meeting size to enable communication with all the participants. Ideal for networking.’ - Peggy Sotiropoulou – Ceylad
Download Agenda
Associate Partner
Event Partners
Media Partners
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
Venue
Hyatt Regency Boston Harbor, 101 Harborside Drive, Boston, MA 02128
Hyatt Regency Boston Harbor
Room rate: $229 exclusive of applicable taxes, double for single occupancy
To make your reservations, please click here: https://www.hyatt.com/en-US/group-booking/BOSHA/G-03KS
If you need additional assistance, please contact us at 877-803-7534 or click here to find contact information by Region.
If the group rate is no longer available, prevailing rates may be offered for some or all of your dates.
Book by 19th February 2019.
After this date rates are subject to availability.
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
